Print

News

  • Committing to Global Health: Balancing Access and Sustainability key to success

    Warsaw, Poland, 13 June 2019 - Generic, biosimilar and value added medicine manufacturers deliver increased access to medicines worldwide. This access could be threatened by shortsighted cost-containment policies that make manufacturing and supply unsustainable. Focused pharmaceutical policies based on healthy competition, Read More
  • Contribution of the generic and biosimilar medicines industries to the 2030 United Nations Agenda for Sustainable Development - Universal Health Coverage

    Geneva, 20 May 2019 - Generic and biosimilar medicines have improved the quality of life of patients all over the world by increasing access to high-quality medicines. It is useful to report data that shows the actual impact of generic and Read More
  • IGBA congratulates health Canada for decision on biologics naming that supports growing global consensus

    Geneva, 27 February 2019 - The International Generic and Biosimilar medicines Association (IGBA) welcomes Health Canada’s decision to proceed with a biologic naming policy that identifies all biologic medicines, including biosimilars, by their unique brand name and non-proprietary (common) name, without Read More
  • Statement on the Passing of Dilip Shah

    February 22, 2019 – Toronto – The following is a statement by Jim Keon, Chair of the International Generic and Biosimilars medicines Association (IGBA), on the passing of Dilip Shah, Secretary-General of the Indian Pharmaceutical Association (IPA). Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11

Print

Vision and Mission

Our vision is to promote the widest possible access to generic and biosimilar medicines with high quality, safety and efficacy, support international harmonized pathways for the registration of those medicines, and a strong commitment by members to standards agreed by the International Council for Harmonization (ICH) and WHO accredited regulators.

Print

The IGBA

In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.

The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. To reflect the evolving nature of the industry, in late 2015, IGPA incorporated under Swiss Law, and at the same time changed the name of the organization to the International Generic and Biosimilar Medicines Association (IGBA). 

Annual Conference - Warsaw 2019

Annual Conference - Budapest 2018

Annual Conference - Lisboa 2017

Contact Info

2019-03-18IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

Rue des Pierres-du-Niton 17
1207 Geneva

Telephone: +32 (0)2 5346607
E-mails: 
This email address is being protected from spambots. You need JavaScript enabled to view it.  
or 
This email address is being protected from spambots. You need JavaScript enabled to view it.

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site